Get the Stockscreener App
5.25
2.60%
-0.14
After Hours:
5.27
0.02
+0.38%
Aldeyra Therapeutics Inc stock is traded at $5.25, with a volume of 780.93K.
It is down -2.60% in the last 24 hours and down -2.60% over the past month.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
See More
Previous Close:
$5.39
Open:
$5.4
24h Volume:
780.93K
Relative Volume:
0.88
Market Cap:
$314.45M
Revenue:
-
Net Income/Loss:
$-44.80M
P/E Ratio:
-7.00
EPS:
-0.75
Net Cash Flow:
$-30.67M
1W Performance:
-4.72%
1M Performance:
-2.60%
6M Performance:
+174.87%
1Y Performance:
-2.23%
1-Day Range:
$5.12
$5.47
1-Week Range:
$5.12
$5.78
52-Week Range:
$1.14
$7.20
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Name
Aldeyra Therapeutics Inc
Sector
Industry
Phone
781-761-4904
Address
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
5.25 | 323.65M | 0 | -44.80M | -30.67M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-03-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-02-24 | Resumed | H.C. Wainwright | Buy |
| Apr-27-22 | Resumed | H.C. Wainwright | Buy |
| Feb-08-21 | Initiated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Oct-30-20 | Initiated | Jefferies | Buy |
| Oct-16-20 | Initiated | BTIG Research | Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| May-12-20 | Initiated | Oppenheimer | Outperform |
| Dec-04-18 | Initiated | Citigroup | Buy |
| Sep-26-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Janney | Buy |
| Jan-26-18 | Initiated | Seaport Global Securities | Buy |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Jul-01-16 | Initiated | Stifel | Buy |
| Jul-01-15 | Initiated | Canaccord Genuity | Buy |
| Mar-25-15 | Initiated | Chardan Capital Markets | Buy |
| Mar-20-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-14 | Initiated | H.C. Wainwright | Buy |
| Jun-19-14 | Initiated | Aegis Capital | Buy |
View All
Aldeyra Therapeutics Inc Stock (ALDX) Latest News
Why analysts upgrade Aldeyra Therapeutics Inc. stock2025 Dividend Review & Verified Entry Point Detection - newser.com
Evaluating Aldeyra Therapeutics Inc. with trendline analysisJuly 2025 Macro Moves & AI Forecasted Stock Moves - newser.com
Risk adjusted return profile for Aldeyra Therapeutics Inc. analyzed2025 Volume Leaders & Growth Focused Entry Reports - newser.com
Aldeyra Therapeutics (NASDAQ:ALDX) Stock Price Passes Below 50-Day Moving AverageShould You Sell? - MarketBeat
Relative strength of Aldeyra Therapeutics Inc. in sector analysis - newser.com
When is the best time to exit Aldeyra Therapeutics Inc.Quarterly Trade Summary & Weekly Consistent Profit Watchlists - newser.com
Statistical indicators supporting Aldeyra Therapeutics Inc.’s strengthInsider Selling & Fast Gain Swing Alerts - newser.com
How to forecast Aldeyra Therapeutics Inc. trends using time seriesTrend Reversal & Consistent Growth Stock Picks - newser.com
Is Aldeyra Therapeutics Inc. stock reversal real or fakeWeekly Trade Report & Safe Capital Growth Trade Ideas - newser.com
4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals - Benzinga
Analyzing recovery setups for Aldeyra Therapeutics Inc. investorsJuly 2025 Volume & Verified High Yield Trade Plans - newser.com
Jefferies raises Aldeyra Therapeutics stock price target to $7 on FDA acceptance - Investing.com Canada
Aldeyra Therapeutics' (ALDX) "Sell (E+)" Rating Reaffirmed at Weiss Ratings - MarketBeat
4 Biotech Stocks Seeing Explosive Momentum GainsAldeyra Therapeutics (NASDAQ:ALDX) - Benzinga
Will Aldeyra Therapeutics Inc. see short term momentum2025 Breakouts & Breakdowns & Low Risk Investment Opportunities - newser.com
How to track smart money flows in Aldeyra Therapeutics Inc.Quarterly Profit Review & Short-Term High Return Strategies - newser.com
Is this a good reentry point in Aldeyra Therapeutics Inc.July 2025 Analyst Calls & Low Risk Investment Opportunities - newser.com
Using Ichimoku Cloud for Aldeyra Therapeutics Inc. technicalsMarket Weekly Review & Precise Swing Trade Alerts - newser.com
Can Aldeyra Therapeutics Inc. rally from current levels2025 Market Sentiment & Free Safe Entry Trade Signal Reports - newser.com
PFG Investments LLC Has $985,000 Holdings in Aldeyra Therapeutics, Inc. $ALDX - MarketBeat
Exploring 3 High Growth Tech Stocks in the US Market - simplywall.st
Aldeyra Therapeutics (NASDAQ:ALDX) Stock Price Passes Below Fifty Day Moving AverageWhat's Next? - MarketBeat
Multi factor analysis applied to Aldeyra Therapeutics Inc.Quarterly Growth Report & AI Forecast Swing Trade Picks - newser.com
ALDX stock touches 52-week high at $6.6 amid robust annual gains - MSN
High Growth Tech Stocks In The US For September 2025 - simplywall.st
High Growth Tech Stocks In The US Market With Promising Potential - Yahoo Finance
What analysts say about Aldeyra Therapeutics Inc stockFibonacci Extensions & Free Rapid Growing Investment Returns - earlytimes.in
Aldeyra Therapeutics Inc Stock Analysis and ForecastSector ETF Performance & Exceptional Capital Growth - earlytimes.in
Aldeyra Therapeutics Stock Surges on Key Regulatory Advancements - AD HOC NEWS
Goldman Sachs Group Inc. Sells 115,969 Shares of Aldeyra Therapeutics, Inc. $ALDX - Defense World
Aldeyra Therapeutics Inc Stock (ALDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aldeyra Therapeutics Inc Stock (ALDX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Machatha Stephen | Chief Development Officer |
Aug 11 '25 |
Sale |
5.15 |
22,073 |
113,713 |
221,799 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):